These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35841843)

  • 1. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.
    Leone JP; Graham N; Tolaney SM; Leone BA; Freedman RA; Hassett MJ; Leone J; Vallejo CT; Winer EP; Lin NU; Tayob N
    Eur J Cancer; 2022 Sep; 173():20-29. PubMed ID: 35841843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool.
    Leone JP; Graham N; Leone J; Tolaney SM; Leone BA; Freedman RA; Hassett MJ; Vallejo CT; Winer EP; Lin NU; Tayob N
    Eur J Cancer; 2023 Aug; 189():112930. PubMed ID: 37356327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.
    Leone J; Hassett MJ; Freedman RA; Tolaney SM; Graham N; Tayob N; Vallejo CT; Winer EP; Lin NU; Leone JP
    JAMA Oncol; 2024 Apr; 10(4):508-515. PubMed ID: 38421673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with late risks of breast cancer-specific mortality in the SEER registry.
    Leone JP; Vallejo CT; Hassett MJ; Leone J; Graham N; Tayob N; Freedman RA; Tolaney SM; Leone BA; Winer EP; Lin NU
    Breast Cancer Res Treat; 2021 Aug; 189(1):203-212. PubMed ID: 33893907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
    Leone JP; Leone BA; Tayob N; Hassett MJ; Leone J; Freedman RA; Tolaney SM; Winer EP; Vallejo CT; Lin NU
    Breast Cancer Res Treat; 2021 Jun; 187(3):843-852. PubMed ID: 33590387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
    Yu KD; Wu J; Shen ZZ; Shao ZM
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
    Hanrahan EO; Gonzalez-Angulo AM; Giordano SH; Rouzier R; Broglio KR; Hortobagyi GN; Valero V
    J Clin Oncol; 2007 Nov; 25(31):4952-60. PubMed ID: 17971593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
    Liu YR; Jiang YZ; Yu KD; Shao ZM
    Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating overall survival and competing risks of survival in patients with early-stage breast cancer using a comprehensive nomogram.
    Xu YB; Liu H; Cao QH; Ji JL; Dong RR; Xu D
    Cancer Med; 2020 Jun; 9(12):4095-4106. PubMed ID: 32314546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.
    Zhou P; Zhang WW; Bao Y; Wang J; Lian CL; He ZY; Wu SG
    Breast; 2020 Dec; 54():319-327. PubMed ID: 33278648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study.
    Bao J; Yu KD; Jiang YZ; Shao ZM; Di GH
    PLoS One; 2014; 9(4):e94815. PubMed ID: 24740002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying the relationship between age at diagnosis and breast cancer-specific mortality.
    Johnson HM; Irish W; Muzaffar M; Vohra NA; Wong JH
    Breast Cancer Res Treat; 2019 Oct; 177(3):713-722. PubMed ID: 31297648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy.
    Li J; Jiang Y; Liu Y; Shao Z
    Breast; 2017 Feb; 31():173-180. PubMed ID: 27866092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods.
    Li J; Liu Y; Jiang Y; Shao Z
    PLoS One; 2016; 11(6):e0157322. PubMed ID: 27299729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis.
    Johnson HM; Irish W; Vohra NA; Wong JH
    Breast Cancer Res Treat; 2019 Aug; 177(1):155-164. PubMed ID: 31127469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis.
    Cai S; Zuo W; Lu X; Gou Z; Zhou Y; Liu P; Pan Y; Chen S
    Front Oncol; 2020; 10():1729. PubMed ID: 33072554
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
    Petkov VI; Miller DP; Howlader N; Gliner N; Howe W; Schussler N; Cronin K; Baehner FL; Cress R; Deapen D; Glaser SL; Hernandez BY; Lynch CF; Mueller L; Schwartz AG; Schwartz SM; Stroup A; Sweeney C; Tucker TC; Ward KC; Wiggins C; Wu XC; Penberthy L; Shak S
    NPJ Breast Cancer; 2016; 2():16017. PubMed ID: 28721379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
    BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study.
    Zheng YZ; Wang XM; Fan L; Shao ZM
    Oncologist; 2021 Feb; 26(2):e241-e250. PubMed ID: 33075188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.